July 14, 2025

Figure 2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

View Full Paper

Ask AI

Bookmark

MAIN FINDING: The trial explores TP-0903 and decitabine's effectiveness in patients with acute myeloid leukemia aged 60 and older.
KEY EVIDENCE: Results indicate a correlation between baseline mutations in tp53 and treatment response for those with acute myeloid leukemia.
APPROACH: A Phase 1b/2 study design was employed, targeting mutations and karyotype abnormalities in the patient population.
SIGNIFICANCE: Findings suggest a promising approach for targeting difficult-to-treat mutations in older adults with acute myeloid leukemia.

Authors

Discussion

No takes yet. Share an insight, caveat, or question.

Phase 1b/2 trial shows efficacy of TP-0903 and decitabine in treating acute myeloid leukemia, implying potential for older patients.

Eisenmann et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark